About: http://data.cimple.eu/news-article/681210bab03955ff1bebacfdea156ceb636cd8b3b2e3325320117f0e

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: http://data.cimple.eu/news-article/681210bab03955ff1bebacfdea156ceb636cd8b3b2e3325320117f0e Goto Sponge NotDistinct Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

Attributes	Values
rdf:type	schema:NewsArticle
schema:articleBody	Altasciences is pleased to have contributed to the recent FDA approval of Vibegron, by performing three early phase clinical trials. Vibegron is a beta-3 adrenergic receptor (?3) agonist, for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence (UUI), urgency, and urinary frequency in adults. The approval was announced by Urovant Sciences on December 23, 2020. "We take tremendous pride in contributing to the FDA approval of much-needed medicines that improve the health and wellbeing of patients,"said Amy Denvir, General Manager at Altasciences' Kansas clinical pharmacology unit. "Working with Urovant Sciences on this program has been a pleasure, and we are delighted to see it come to fruition." Altasciences' expert clinical teams provided clinical support for two drug-drug interaction studies and a bioavailability trial, conducted in 2018 and 2019, in healthy subjects. These trials were supported by Altasciences' data services team, who performed the full data management and reporting for the associated clinical studies. About Altasciences Altasciences is a forward-thinking, mid-size contract research organization offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services. For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences' integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster. View source version on businesswire.com: Contact Julie-Ann Cabana Altasciences +1 514 601-9763 jcabana@altasciences.com © 2021 Business Wire, Inc. Disclaimer: This material is not an AFP editorial material, and AFP shall not bear responsibility for the accuracy of its content. In case you have any questions about the content, kindly refer to the contact person/entity mentioned in the text of the release.
schema:headline	Press Release from Business Wire: Altasciences
schema:mentions	Biotechnology Amy Pond Urinary incontinence Contact (1997 American film) Urge (digital music service) Overactive bladder Sport utility vehicle Medication Kansas Bear General officer Food and Drug Administration Beta-3 adrenergic receptor Frequent urination Clinical pharmacology Bioanalysis Agonist Bioavailability Biostatistics Drug interaction Data management Drug development Alpha-fetoprotein Business Wire
schema:author	http://data.cimple.eu/organization/1f0054d541e000623a2c1e561a247c073ef6328e8be9ffafda7b3fcd
schema:datePublished	2021-02-23 (xsd:date)
http://data.cimple...sPoliticalLeaning	other political leaning
http://data.cimple...logy#hasSentiment	positive sentiment
http://data.cimple...readability_score	85 (xsd:integer)
http://data.cimple...tology#hasEmotion	happiness

Faceted Search & Find service v1.16.115 as of Oct 09 2023

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 5 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software